[Markers of effectiveness of preoperative taxane-based chemotherapy for locally advanced breast cancer]

Autor: Semiglazova TIu, Vv, Klimenko, Lv, Filatova, Va, Chubenko, Pv, Krivorot Ko, Vg, Ivanov, Ea, Turkevich, Ao, Ivantsov, Sn, Novikov, Vv, Semiglazov, Rv, Donskikh, Fedor Moiseenko, Ea, Bus Ko, Briantseva ZhV, Ma, Osipov, Ml, Gershanovish, En, Imianitov, Vf, Semiglazov

Publikováno v: Europe PubMed Central

The absolute sensitivity signs of breast cancer to the drug have not yet been developed. Data from clinical trials on the study of experimental laboratory predictive markers of chemosensitivity: TOP2alpha (topoisomerase 2-alpha), beta-tubulin (subuni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1cc97a188477768b8058f4f63d8c9402
http://europepmc.org/abstract/med/23909039

Neoadjuvant Immunotherapy Effectiveness in Patients With Microsatellite Instability-High (MSI-H) Gastric Cancer.

Autor: Chubenko VA; Department of Chemotherapy, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS., Navmatulya AY; Department of Abdominal Surgery, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS., Gerk IA; Department of Chemotherapy, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS., Sarmatov AA; Department of Chemotherapy, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS., Egorenkov VV; Department of Surgery, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS., Shelekhova KA; Department of Pathology, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS., Zykov EN; Department of Radioisotope, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS., Chernobrivceva VV; Department of Radiology, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS., Volkov NM; Department of Medical and Radiation Therapy, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS., Moiseyenko VM; Department of the Director, Napalkov State Budgetary Healthcare Institution, Saint Petersburg Clinical, Scientific, and Practical Center for Specialised Types of Medical Care (Oncological), Saint Petersburg, RUS.

Publikováno v: Cureus [Cureus] 2024 May 30; Vol. 16 (5), pp. e61344. Date of Electronic Publication: 2024 May 30 (Print Publication: 2024).

First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.

Autor: Moiseyenko VM; City Cancer Center, Saint Petersburg, 197758, Russia., Moiseyenko FV; City Cancer Center, Saint Petersburg, 197758, Russia.; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; I.I. Mechnikov North-Western Medical University, Saint Petersburg, 191015, Russia., Yanus GA; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Kuligina ES; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Sokolenko AP; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Bizin IV; St. Petersburg State Polytechnical University, Saint Petersburg, 195251, Russia., Kudriavtsev AA; City Cancer Center, Saint Petersburg, 197758, Russia., Aleksakhina SN; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Volkov NM; City Cancer Center, Saint Petersburg, 197758, Russia., Chubenko VA; City Cancer Center, Saint Petersburg, 197758, Russia., Kozyreva KS; City Cancer Center, Saint Petersburg, 197758, Russia., Kramchaninov MM; City Cancer Center, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Zhuravlev AS; City Cancer Center, Saint Petersburg, 197758, Russia., Shelekhova KV; City Cancer Center, Saint Petersburg, 197758, Russia., Pashkov DV; S.M. Kirov Military Medical Academy, Saint Petersburg, 194044, Russia., Ivantsov AO; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Venina AR; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Sokolova TN; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Preobrazhenskaya EV; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Mitiushkina NV; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia., Togo AV; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Iyevleva AG; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia., Imyanitov EN; City Cancer Center, Saint Petersburg, 197758, Russia. evgeny@imyanitov.spb.ru.; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, Saint Petersburg, 197758, Russia. evgeny@imyanitov.spb.ru.; I.I. Mechnikov North-Western Medical University, Saint Petersburg, 191015, Russia. evgeny@imyanitov.spb.ru.; St. Petersburg Pediatric Medical University, Saint Petersburg, 194100, Russia. evgeny@imyanitov.spb.ru.; St. Petersburg State University, Saint Petersburg, 199034, Russia. evgeny@imyanitov.spb.ru.

Publikováno v: Clinical drug investigation [Clin Drug Investig] 2018 Jun; Vol. 38 (6), pp. 553-562.

Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.

Autor: Moiseyenko FV; City Cancer Center, St.-Petersburg, Russia., Moiseyenko VM, Aleksakhina SN, Chubenko VA, Volkov NM, Kozyreva KS, Kramchaninov MM, Zhuravlev AS, Shelekhova KV, Ivantsov AO, Venina AR, Preobrazhenskaya EV, Mitiushkina NV, Iyevleva AG, Imyanitov EN

Publikováno v: Oncology research and treatment [Oncol Res Treat] 2016; Vol. 39 (10), pp. 605-614. Date of Electronic Publication: 2016 Sep 15.

[Therapeutic activity of gemcitabine in intracranial tumors].

Autor: Stukov AN, Filatova LV, Latipova DKh, Bespalov VG, Belyaeva OA, Kireeva GS, Vasilieva IN, Alexandrov VA, Maidin MA, Semenov AL, Vershinina SF, Markochev AB, Abduloeva NKh, Chubenko VA, Semiglazova TY

Publikováno v: Voprosy onkologii [Vopr Onkol] 2015; Vol. 61 (2), pp. 274-9.